Q3 2025 Alvotech SA Earnings Call (French) Transcript
Key Points
- Alvotech (ALVO) reported a strong revenue growth of 420% in 2024 and is guiding approximately 20% growth for 2025.
- The company has a robust pipeline with 5 approved biosimilars and 12 other disclosed development programs, targeting over $185 billion of originator markets.
- Alvotech (ALVO) has expanded its R&D capabilities with a new operational base in Sweden, enhancing its research and development initiatives.
- The company holds the second largest market share in the Humira biosimilar segment in the US and is the fastest-growing Humira biosimilar.
- Alvotech (ALVO) has a strong global presence, commercializing through a network of nearly 20 partners, reaching over 90 countries worldwide.
- Alvotech (ALVO) received a complete response letter (CRL) from the FDA for its BLA for the proposed biosimilar to Simponi due to unresolved issues at its Reykjavik facility.
- The company revised its full-year revenue outlook to $570 million to $600 million, down from previous expectations, due to the CRL and related production slowdowns.
- There is a temporary loss in product revenues related to facility improvements, impacting the company's financial performance in 2025.
- Alvotech (ALVO) faces challenges in maintaining FDA compliance, with recent inspections resulting in multiple observations that require significant improvements.
- The company's adjusted EBITDA margin for the first nine months of 2025 was 16%, down from 26% last year, due to higher R&D investments and operational costs.
Good day, and thank you for standing by. Welcome to the Alvotech Q3 2025 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Benedikt Stefansson, Vice President of Investor Relations and Global Communications. Please go ahead.
Thank you, and welcome to our listeners. Yesterday evening, the company issued a press release announcing our financial results for the first nine months and third quarter of 2025. A presentation accompanying today's earnings call was also published under our investor portal, investors.alvotech.com, under News & Events.
Our press release, presentation and statements that we make on the call today may include forward-looking statements. Please see our disclaimers on slide number 2 of the presentation. These statements do not ensure future performance and are subject to risks and uncertainties that are
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
